University of Belgrade, Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia.
Bioorg Med Chem. 2012 Sep 1;20(17):5220-8. doi: 10.1016/j.bmc.2012.06.051. Epub 2012 Jul 11.
A set of 16 previously synthesized aryl-aminopyridine and aryl-aminoquinoline derivatives have been evaluated for cytotoxic activity against three cancer cell lines (human cervical cancer-HeLa; human chronic myeloid leukemia-K562; human melanoma-Fem-x) and two types of normal peripheral blood mononuclear cells, with and without phytohemaglutinin (PBMC-PHA; PBMC+PHA). Twelve of the studied compounds showed moderate cytotoxicity, with selectivity against K562 but not the remaining two cancer cell lines. Four compounds were not active in cytotoxicity assays, presumably due to high predicted lipophilicity and low solubility. To rationalize the observed cytotoxic effects, structure-based virtual screening was carried out against a pool of potential targets constructed using the inverse docking program Tarfisdock and bibliographical references. The putative targets were identified on the basis of the best correlation between docking scores and in vitro cytotoxicity. It is proposed that the mechanism of action of the studied aminopyridines involves the disruption of signaling pathways and cancer cell cycle through the inhibition of cyclin-dependent kinases and several tyrosine kinases, namely Bcr-Abl kinase and KIT receptor kinase. The obtained results can guide further structural modifications of the studied compounds aimed at developing selective agents targeting proteins involved in cancer cell survival and proliferation.
已评估了一组 16 种先前合成的芳基-氨基吡啶和芳基-氨基喹啉衍生物对三种癌细胞系(人宫颈癌-HeLa;人慢性髓性白血病-K562;人黑色素瘤-Fem-x)和两种类型的正常外周血单个核细胞(有植物血球凝集素和无植物血球凝集素的外周血单个核细胞-PBMC-PHA 和 PBMC+PHA)的细胞毒性活性。在所研究的 12 种化合物中,有 12 种具有中等细胞毒性,对 K562 具有选择性,但对其余两种癌细胞系没有选择性。四种化合物在细胞毒性测定中没有活性,可能是由于预测的亲脂性高和溶解度低。为了合理化观察到的细胞毒性作用,使用反向对接程序 Tarfisdock 和文献参考,针对潜在靶标池进行了基于结构的虚拟筛选。根据对接评分与体外细胞毒性之间的最佳相关性,确定了假定的靶标。据推测,所研究的氨基吡啶的作用机制涉及通过抑制周期蛋白依赖性激酶和几种酪氨酸激酶(即 Bcr-Abl 激酶和 KIT 受体激酶)破坏信号通路和癌细胞周期。获得的结果可以指导进一步的结构修饰,以开发针对参与癌细胞存活和增殖的蛋白质的选择性试剂。